Evaluation of PTTG-1 (pituitary tumor transforming gene 1) gene expression in iodine refractory papillary thyroid carcinoma

Papillary Thyroid Cancer (PTC) is the most common species of thyroid cancers. Although PTC's prognosis is usually good, the prognosis of radioactive iodine refractory (RAI-R) patients who cannot respond to radioactive iodine (RAI) treatment is quite bad. Molecular mechanisms have been emphasized in PTC pathogenesis in recent years. Pituitary Tumor Transforming Gene-1 (PTTG-1) is a proto-oncogene associated with thyroid cancers in some studies. A total of 53 people were included in our study, including 26 RAI-R PTC, 15 classic PTC, 12 multinodular goiter (MNG) control patient. In our study, it was found that PTTG-1 gene expression changes were not statistically significant than PTC in RAI-R PTC, but higher (1.99 vs 1.73, p = 0.751). This may contribute to the fact that RAI-R PTCs take less iodine and their response to RAI ablation therapy. In RAI-R PTC patients, there was no significant relationship between PTTG-1 gene expression level and TG, anti-TG, NLR, age, metastasis diameter, tumor splitting time, suvmax values and gender (p> 0.05). In order to better understand the role of PTTG-1 in PTC, further studies are required by using microscopic samples made in more patients and only to obtain tumor tissue by using a healthy control group instead of MNG in the future.